Faes Farma Future Growth

Future criteria checks 0/6

Faes Farma's earnings are forecast to decline at 1.9% per annum while its annual revenue is expected to grow at 1.6% per year. EPS is expected to decline by 2% per annum. Return on equity is forecast to be 11.3% in 3 years.

Key information

-1.9%

Earnings growth rate

-2.0%

EPS growth rate

Pharmaceuticals earnings growth13.9%
Revenue growth rate1.6%
Future return on equity11.3%
Analyst coverage

Low

Last updated29 Apr 2024

Recent future growth updates

Recent updates

Faes Farma, S.A. (BME:FAE) Just Released Its Full-Year Earnings: Here's What Analysts Think

Mar 01
Faes Farma, S.A. (BME:FAE) Just Released Its Full-Year Earnings: Here's What Analysts Think

Faes Farma (BME:FAE) Is Due To Pay A Dividend Of €0.0316

Dec 18
Faes Farma (BME:FAE) Is Due To Pay A Dividend Of €0.0316

Faes Farma (BME:FAE) Will Pay A Dividend Of €0.0316

Dec 04
Faes Farma (BME:FAE) Will Pay A Dividend Of €0.0316

Does Faes Farma (BME:FAE) Have A Healthy Balance Sheet?

Nov 24
Does Faes Farma (BME:FAE) Have A Healthy Balance Sheet?

Here's Why Faes Farma (BME:FAE) Can Manage Its Debt Responsibly

May 03
Here's Why Faes Farma (BME:FAE) Can Manage Its Debt Responsibly

Is There An Opportunity With Faes Farma, S.A.'s (BME:FAE) 50% Undervaluation?

Sep 21
Is There An Opportunity With Faes Farma, S.A.'s (BME:FAE) 50% Undervaluation?

Is Faes Farma (BME:FAE) A Risky Investment?

Aug 03
Is Faes Farma (BME:FAE) A Risky Investment?

Faes Farma (BME:FAE) Ticks All The Boxes When It Comes To Earnings Growth

Jun 17
Faes Farma (BME:FAE) Ticks All The Boxes When It Comes To Earnings Growth

Is Faes Farma (BME:FAE) Using Too Much Debt?

Mar 27
Is Faes Farma (BME:FAE) Using Too Much Debt?

Faes Farma (BME:FAE) Is Increasing Its Dividend To €0.14

Dec 13
Faes Farma (BME:FAE) Is Increasing Its Dividend To €0.14

Faes Farma's (BME:FAE) Dividend Will Be Increased To €0.17

Nov 29
Faes Farma's (BME:FAE) Dividend Will Be Increased To €0.17

Is Faes Farma (BME:FAE) A Risky Investment?

Sep 21
Is Faes Farma (BME:FAE) A Risky Investment?

Faes Farma, S.A. (BME:FAE) Interim Results: Here's What Analysts Are Forecasting For This Year

Jul 31
Faes Farma, S.A. (BME:FAE) Interim Results: Here's What Analysts Are Forecasting For This Year

Is Faes Farma (BME:FAE) Using Too Much Debt?

May 01
Is Faes Farma (BME:FAE) Using Too Much Debt?

Estimating The Fair Value Of Faes Farma, S.A. (BME:FAE)

Apr 07
Estimating The Fair Value Of Faes Farma, S.A. (BME:FAE)

Does Faes Farma, S.A. (BME:FAE) Have A Place In Your Dividend Portfolio?

Mar 22
Does Faes Farma, S.A. (BME:FAE) Have A Place In Your Dividend Portfolio?

Faes Farma's (BME:FAE) Solid Earnings May Rest On Weak Foundations

Mar 06
Faes Farma's (BME:FAE) Solid Earnings May Rest On Weak Foundations

Faes Farma (BME:FAE) Has Compensated Shareholders With A Respectable 61% Return On Their Investment

Feb 22
Faes Farma (BME:FAE) Has Compensated Shareholders With A Respectable 61% Return On Their Investment

I Ran A Stock Scan For Earnings Growth And Faes Farma (BME:FAE) Passed With Ease

Jan 16
I Ran A Stock Scan For Earnings Growth And Faes Farma (BME:FAE) Passed With Ease

Faes Farma (BME:FAE) Seems To Use Debt Rather Sparingly

Dec 08
Faes Farma (BME:FAE) Seems To Use Debt Rather Sparingly

Earnings and Revenue Growth Forecasts

BME:FAE - Analysts future estimates and past financials data (EUR Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/20264998994N/A3
12/31/20254979279N/A4
12/31/20244769055N/A3
3/31/202448295N/AN/AN/A
12/31/202347392-1101N/A
9/30/202347290N/AN/AN/A
6/30/202346990-997N/A
3/31/202346791N/AN/AN/A
12/31/20224628926107N/A
9/30/202246086N/AN/AN/A
6/30/20224668850113N/A
3/31/202244988N/AN/AN/A
12/31/2021429822080N/A
9/30/202141681N/AN/AN/A
6/30/202139874856N/A
3/31/202139473N/AN/AN/A
12/31/2020411735378N/A
9/30/202040877N/AN/AN/A
6/30/2020407735778N/A
3/31/202040968N/AN/AN/A
12/31/2019383644668N/A
9/30/201937960N/AN/AN/A
6/30/2019363595174N/A
3/31/201935154N/AN/AN/A
12/31/2018340524059N/A
9/30/201833451N/AN/AN/A
6/30/2018330494058N/A
3/31/201830847N/AN/AN/A
12/31/201728241N/A42N/A
9/30/201726639N/AN/AN/A
6/30/201725039N/A43N/A
3/31/201724138N/AN/AN/A
12/31/201623737N/A50N/A
9/30/201622635N/AN/AN/A
6/30/201622234N/A40N/A
3/31/201622032N/AN/AN/A
12/31/201521430N/A41N/A
9/30/201520728N/AN/AN/A
6/30/201520327N/A42N/A
3/31/201519626N/AN/AN/A
12/31/201419825N/A32N/A
9/30/201419523N/AN/AN/A
6/30/201419424N/A20N/A
3/31/201419220N/AN/AN/A
12/31/201319323N/A32N/A
9/30/201319621N/AN/AN/A
6/30/201319723N/A31N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: FAE's earnings are forecast to decline over the next 3 years (-1.9% per year).

Earnings vs Market: FAE's earnings are forecast to decline over the next 3 years (-1.9% per year).

High Growth Earnings: FAE's earnings are forecast to decline over the next 3 years.

Revenue vs Market: FAE's revenue (1.6% per year) is forecast to grow slower than the Spanish market (4% per year).

High Growth Revenue: FAE's revenue (1.6% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: FAE's Return on Equity is forecast to be low in 3 years time (11.3%).


Discover growth companies

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.